CD229 is expressed on the surface of plasma cells carrying an aberrant phenotype and chemotherapy-resistant precursor cells in Multiple MyelomaSara Yousef, Djordje Atanackovic, Magdalena Kovacsovics-Bankowski et al.|Clinical Lymphoma Myeloma & Leukemia|2015Cited by 1
Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Megan Othus et al.|Unknown|2023Cited by 0
Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Megan Othus et al.|Unknown|2023Cited by 0
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Elizabeth I. Buchbinder et al.|Unknown|2023Cited by 0
Supplementary Data from Adjuvant Pembrolizumab versus IFNα2b or Ipilimumab in Resected High-Risk MelanomaKenneth F. Grossmann, Antoni Ribas, Megan Othus et al.|Unknown|2023Cited by 0